Le dernier exercice comptable publié pour cette entreprise remonte à 2022. Les données ci-dessous peuvent ne plus refléter sa situation actuelle.

INTESTINAL BIOTECH DEVELOPMENT : revenue, balance sheet and financial ratios

INTESTINAL BIOTECH DEVELOPMENT is a French company founded 18 years ago, specialized in the sector Recherche-développement en biotechnologie. Based in LILLE (59000), this company of category PME shows in 2022 a revenue of 747 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-07-11

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Synthèse

Santé financière : Fragile

Signal structurel : résultat d'exploitation insuffisant pour couvrir les intérêts.

In summary, INTESTINAL BIOTECH DEVELOPMENT posts positive profitability over the latest financial year. Its financial structure is solid, with debt well contained relative to its sector.

Financial history - INTESTINAL BIOTECH DEVELOPMENT (SIREN 503698193)
Indicator 2024 2023 2022 2021
Revenue N/C N/C 747 109 € 808 406 €
Net income 106 646 € 149 940 € 185 188 € 274 262 €
EBITDA N/C N/C 222 184 € 302 207 €
Net margin N/C N/C 24.8% 33.9%

Revenue and income statement

In 2024, INTESTINAL BIOTECH DEVELOPMENT generates positive net income of 107 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2021-2024: 274 k€ -> 107 k€.

Revenue (2022) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

747 109 €

Gross margin (2022) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

747 109 €

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

222 184 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

188 713 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

185 188 €

EBITDA margin (2022) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

27.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. Compared with its sector, this ratio places the company among the best positioned (sector median: 14.7%). Financial autonomy (= Equity / Total assets x 100) reaches 75%. Compared with its sector, this ratio places the company among the best positioned (sector median: 53.9%). Cash flow represents 23.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This ratio is more favorable than the sector median (8.5%).

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.01%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

75.32%

Cash flow / Revenue (2022) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

23.13%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

10.9%

Solvency indicators evolution
INTESTINAL BIOTECH DEVELOPMENT

Sector positioning

Debt ratio
0.0% 2024
Q1: 0.18%
Med: 14.73%
Q3: 59.82%
Excellent

In 2024, the debt ratio of INTESTINAL BIOTECH DEVELO... (0.0%) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
81.96% 2024
Q1: 31.16%
Med: 53.86%
Q3: 76.06%
Excellent +6 pts over 3 years

In 2024, the financial autonomy of INTESTINAL BIOTECH DEVELO... (82.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 9.09. This ratio is more favorable than the sector median (3.7). The interest coverage ratio (= EBIT / Interest expenses) is 0.1x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

9.09

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.05

Liquidity indicators evolution
INTESTINAL BIOTECH DEVELOPMENT

Sector positioning

Liquidity ratio
6.36 2024
Q1: 1.7
Med: 3.7
Q3: 6.72
Good

In 2024, the liquidity ratio of INTESTINAL BIOTECH DEVELO... (6.36) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Overall, WCR represents 125 days of revenue, i.e. 0 € to permanently finance.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

259 561 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

169 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

40 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2022) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

125 j

WCR and payment terms evolution
INTESTINAL BIOTECH DEVELOPMENT

Positioning of INTESTINAL BIOTECH DEVELOPMENT in its sector

Comparison with sector Recherche-développement en biotechnologie

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (36 transactions). This range of 54 628€ to 1 834 216€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
54k€ 398k€ 1834k€
398 114 € Range: 54 628€ - 1 834 216€
NAF 4 all-time Aggregated at NAF sub-class level
How is this estimate calculated?

This estimate is based on the analysis of 36 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Recherche-développement en biotechnologie)

Compare INTESTINAL BIOTECH DEVELOPMENT with other companies in the same sector:

Voir toutes les statistiques du secteur Recherche-développement en biotechnologie

Top companies in Recherche-développement en biotechnologie

Largest companies by revenue in the sector Recherche-développement en biotechnologie:

Top companies in Nord

Largest companies by revenue in the department Nord:

Voir le classement complet du département Nord

Frequently asked questions about INTESTINAL BIOTECH DEVELOPMENT

What is the revenue of INTESTINAL BIOTECH DEVELOPMENT ?

The revenue of INTESTINAL BIOTECH DEVELOPMENT in 2022 is 747 k€.

Is INTESTINAL BIOTECH DEVELOPMENT profitable?

Yes, INTESTINAL BIOTECH DEVELOPMENT generated a net profit of 107 k€ in 2024.

Where is the headquarters of INTESTINAL BIOTECH DEVELOPMENT ?

The headquarters of INTESTINAL BIOTECH DEVELOPMENT is located in LILLE (59000), in the department Nord.

Where to find the tax return of INTESTINAL BIOTECH DEVELOPMENT ?

The tax return of INTESTINAL BIOTECH DEVELOPMENT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does INTESTINAL BIOTECH DEVELOPMENT operate?

INTESTINAL BIOTECH DEVELOPMENT operates in the sector Recherche-développement en biotechnologie (NAF code 72.11Z). See the 'Sector positioning' section above to compare the company with its competitors.